Language Selector:

Dedicated to
Natural Breathing

Designed to help patients wean off
a ventilator and breathe on their own

Without a strong diaphragm it is impossible to breathe independently*

Artificial breathing support from a ventilator may weaken the diaphragm muscle more than 50% in less than one day* making it difficult to regain independent breathing.

Lungpacer is designed as a personal trainer for the diaphragm muscle*

Lungpacer’s AeroPace system is designed to stimulate the nerves that activate the diaphragm with repetitive exercises for 10-20 minutes twice per day to rebuild diaphragm strength and empower natural, independent breathing*.

Potential Benefits

Wean off a
ventilator faster*

ventilator trauma*

cost and

of survival*

of life*

Our Vision for the Future of Patient Care


Breathing Complications

Ventilator breathing bypasses the brain and diaphragm by forcing air into the lungs causing damage in less than one day


Designed to Empower Natural Breathing

Engage the diaphragm, lungs, and brain
to support natural breathing

Diaphragm: Inactive

Causes muscle weakness and inability to wean off ventilator, long term complications and higher risk of death*

Lungs: Unevenly inflated

Causes lung tissue damage and respiratory complications*

Brain: Signal impaired

Causes cell death and cognitive injury*

Diaphragm: Exercised

Strengthen muscle through stimulated contractions to accelerate ventilator weaning*

Lungs: Naturally inflated

Protect lung tissue and improve lung function*

Brain: Signal normalized

Protect cells linked to cognitive decline due to ventilation*

Outcomes from a Lungpacer Clinical Study Showed

Lungpacer strengthened the diaphragm and improved lung function

246 %
128 %
Lung Function*(RSBI)

Positive trending clinical outcomes

7.4 %
Increase in
Ventilator Weaning*
7.9 %
1.4 Days
Less on a Ventilator*

These results from a randomized, controlled trial compared patients treated with Lungpacer therapy to patients treated with the standard of care. Improvement was statistically significant at p<0.05 for MIP and RSBI; p>0.05 for clinical trends. The rate of serious adverse events was the same between both groups.  No unanticipated adverse device effects.  Device safety events were those commonly reported for central venous catheters.

Lungpacer therapy provides an exciting potential solution to help mechanically ventilated patients return to natural breathing more quickly.
Dr. Joseph Shrager - Stanford University School of Medicine

Lungpacer Medical Research

Scientific Abstracts
& Presentations
Peer Reviewed
10 +

Learn more about results and trends from more than five years of Lungpacer research.

Lungpacer AeroPace™ System

For patients unable to breathe on their own, the AeroPace therapy is designed to provide repetitive exercises, to rebuild diaphragm muscle strength critical to healthy breathing.